medical research archives impact factor 2022

Medical research archives  

Papers published on a yearly basis, utilizing patient hope and outcome expectations to facilitate treatment gains.

47  citations

The Impact of the Role of Doctor of Nursing PracticeNurses on Healthcare and Leadership

22  citations

Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies.

16  citations

Answering Research Questions Using an Existing Data Set

14  citations

Probabilistic Modeling of Blood Vessels for Segmenting Magnetic Resonance Angiography Images

Performance.

• Paper Archives
• Journal Indexing
• Research Conference
• Add Journal

Searching By

• Search More ...

Medical Research Archives (ISSN: 2375-1924)

Publisher European Society of Medicine

ISSN-L 2375-1924

ISSN 2375-1924

IF(Impact Factor) 2024 Evaluation Pending

Website http://esmed.org

Description

Last modified: 2023-05-05 22:47:29

• No Archives

Advertisement

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Evolution of Archives of Medical Research. A Road to Improving Impact Factor

Affiliations.

• 1 Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México. Electronic address: [email protected].
• 2 Editor in Chief, Archives of Medical Research, Cordinación de Investigación en Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
• 3 Associate Editor, Archives of Medical Research, Cordinación de Investigación en Saludo, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
• PMID: 36117054
• DOI: 10.1016/j.arcmed.2022.09.003

PubMed Disclaimer

Similar articles

• The first impact factor for the Polish Archives of Internal Medicine--June 2012. Undas A. Undas A. Pol Arch Med Wewn. 2012;122(7-8):317-9. Pol Arch Med Wewn. 2012. PMID: 22814514 No abstract available.
• Steps to Improve Journal Quality - Example of "Medical Archives". Masic I. Masic I. Med Arch. 2017 Feb;71(1):4-6. doi: 10.5455/medarh.2017.71.4-6. Epub 2017 Feb 5. Med Arch. 2017. PMID: 28428664 Free PMC article. No abstract available.
• Are the Lives of Animals Well-spent in Laboratory Science Research? A Study of Orthopaedic Animal Studies in Turkey. Öztürk A, Ersan Ö. Öztürk A, et al. Clin Orthop Relat Res. 2020 Sep;478(9):1965-1970. doi: 10.1097/CORR.0000000000001335. Clin Orthop Relat Res. 2020. PMID: 32467410 Free PMC article. Review.
• The Archives of Pathology & Laboratory Medicine: The Most Widely Read Pathology Journal Today. Allen TC. Allen TC. Arch Pathol Lab Med. 2016 Sep;140(9):953-5. doi: 10.5858/arpa.2016-0090-SA. Epub 2016 May 3. Arch Pathol Lab Med. 2016. PMID: 27139152
• Impact of the impact factor in biomedical research: its use and misuse. Kumar V, Upadhyay S, Medhi B. Kumar V, et al. Singapore Med J. 2009 Aug;50(8):752-5. Singapore Med J. 2009. PMID: 19710969 Review.

Publication types

• Search in MeSH

LinkOut - more resources

Full text sources.

• Elsevier Science
• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Archives of Medical Research

Journal Abbreviation: ARCH MED RES Journal ISSN: 0188-4409

About Archives of Medical Research

You may also be interested in the following journals

• ► PLoS One
• ► Archivos De Medicina Veterinaria
• ► Progress in Nucleic Acid Research and Molecular Biology
• ► Archives De Pediatrie
• ► Archive For History of Exact Sciences
• ► Annual Review of Entomology
• ► Archivos Latinoamericanos De Nutricion
• ► Archiv Fur Lebensmittelhygiene
• ► Archives of Pediatrics & Adolescent Medicine
• ► Parasitology Research

Top Journals in other

• Ca-A Cancer Journal For Clinicians
• Chemical Reviews
• Nature Materials
• Reviews of Modern Physics
• Nature Reviews Molecular Cell Biology
• Annual Review of Astronomy and Astrophysics
• Cancer Discovery
• BMJ-British Medical Journal
• Advanced Energy Materials
• Advances in Optics and Photonics

Journal Impact

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

28 June 2023 2022 Impact Factors for MDPI Journals

The 2022 citation metrics have been released in the Journal Citation Reports (JCR), and we’re pleased to announce the following results for MDPI journals:

We are thrilled to announce that 90% of our ranked MDPI journals, specifically 86 out of 96 (captured in the table below), are performing above average in Q1 or Q2. This year, Clarivate has expanded its Impact Factor (IF) awards to include journals in the Emerging Sources Citation Index (ESCI) and the Arts and Humanities Citation Index (AHCI), providing greater transparency for the full set of journals indexed in the Web of Science Core Collection . As a result, 111 of MDPI journals have received their first IF in 2023, with 37 journals surpassing an IF of 3.0. In total, 208 MDPI journals have been honored with an IF.

Clarivate explains that by "expanding the coverage but holding to highly selective standards, the [Impact Factor] is now a reliable indicator of trustworthiness, as well as a measure of scholarly impact, at the journal level."

Please visit our blog post where we discuss the release of the latest citation metrics with our Indexing Manager, Dr. Constanze Schelhorn, to find out what's different this time around and how to make use of different metrics available.

Note: The Journal of Personalized Medicine 's Impact Factor was omitted in the original release and will be assigned separately. Please find the data on the journal webpage in due course.

Source: 2022 Journal Impact Factors, Journal Citation Reports TM (Clarivate, 2023)

Further Information

Mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

Quick Links

Support our mission by becoming a member

Public Health Policy Center

Explore the society's public health initiatives

Meet the community

See what our members have been working on

Journal Homepage

Latest issue, past issues, theme issues, top articles, how to submit, article types, style & format, copyright policies, indexing & impact.

Welcome to the European Society of Medicine

Visit our public health policy center.

The European Society of Medicine’s scientific resources translate into compelling advocacy messages to inspire change in healthcare policy. The multitude of backgrounds from which our members come allows us to be stronger, speaking with one voice, when advocating for change, and to consider many perspectives and ideas essential to achieve the society’s mission.

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

If you believe in esmed and everything we stand for, take the next step and support our mission by becoming a member., latest journal articles.

The Medical Research Archives is the official journal of the European Society of Medicine. It publishes original research, reviews, and case reports addressing health issues of interest to a global community of medical professionals. The journal was founded in 2014 and has just published its 119th issue.

Special Issue: Challenges and Opportunities in Health Disparities

Most cited articles.

Primary Central Nervous System Germ Cell Tumors: A Review and Update 98 citations

Pesticides used in Thailand and toxic effects to human health 96 citations

Keeping an Eye on Bardet-Biedl Syndrome: A Comprehensive Review of the Role of Bardet-Biedl Syndrome Genes in the Eye 93 citations

Health of mothers of children with intellectual disability or autism spectrum disorder: a review of the literature 55 citations

The Impact of the Role of Doctor of Nursing PracticeNurses on Healthcare and Leadership 53 citations

Most viewed articles

The Effects of Anabolic Androgenic Steroids on Performance and its Adverse Side Effects in Athletes 306,594 views

Regular sanitizing of cell phones during the Covid-19 pandemic 67,617 views

The Impact of the Role of Doctor of Nursing PracticeNurses on Healthcare and Leadership 59,214 views

Differential diagnosis of tonsillitis, tonsillar detritus accumulation, and tonsillar keratin cysts 52,724 views

The John F. Kennedy X-rays: The saga of the largest “Metallic fragment” 33,066 views

Community hubs

Become a member to gain access to an online community of like-minded doctors in your specialty.

Learn about the benefits of membership, including free article publication.

The Author Center contains a wealth of information on the process of publishing in the society’s journal.

Get a free manuscript evaluation by an editor of the journal within 7 days.

Complete your author registration for an upcoming manuscript submission.

Meet the many people who are part of the European Society of Medicine.

Projects and innitiatives

The European Society of Medicine exists to connect doctors with the knowledge they need to lead medical innovation and reduce the burden of disease.

Working Towards Universal Implementation of Human Papillomavirus Vaccination to Prevent Cervical Cancer

Annekathryn goodman & naima joseph – harvard university school of medicine, call for a new globally equitable vaccine strategy, an open letter to the world health organization, a new model for predicting infectious disease outbreaks, geovax presents covid-19 vaccine data at the european society of medicine general assembly, join the society, professional membership.

• Free publication of 3 articles per year
• Unlimited article evaluations
• Satisfaction guarantee

Membership fee

999 eur/usd, reduced membership.

* Available for these developing nations

• Free publication of 2 articles per year

499 EUR/USD

Information.

Online ISSN: 2375-1924 Print ISSN: 2375-1916 PubMed ID: 101668511

© 2024 European Society of Medicine. All rights reserved.

Call for papers

Have a manuscript to publish in the society's journal?

Search Results

Archives and records-the journal of the archives and records association, international archives of the history of ideas/archives internationales d'histoire des idees, archives of medical research, archives of medical research, archives of medical science, archives of the balkan medical union, archives of medical science, medical archives (sarajevo, bosnia and herzegovina), archives of medical science : ams, archives of medical sciences. atherosclerotic diseases, medical archives, journal of research in medical sciences : the official journal of isfahan university of medical sciences, medical science monitor : international medical journal of experimental and clinical research.

Not getting the journal you are searching for? So it most likely not indexed in Scopus, WOS, PubMed, DOAJ, UGC CARE. You might also try:

• Enter the correct title.
• Check the spelling of the words
• Make sure you have added spaces between words

TOP RESEARCH JOURNALS

• Agricultural & Biological Sciences
• Arts & Humanities
• Business, Management and Accounting
• Computer Science
• Engineering
• Mathematics
• Social Sciences

History of Medicine

Discontinued in Scopus as of 2022

Subject Area and Category

• History and Philosophy of Science
• Medicine (miscellaneous)

Publication type

24095834, 25002910

2014-2019, 2021-2022

Information

How to publish in this journal

[email protected]

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Evolution of the percentage of female authors.

Evolution of the number of documents cited by public policy documents according to Overton database.

Evoution of the number of documents related to Sustainable Development Goals defined by United Nations. Available from 2018 onwards.

Leave a comment

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Follow us on @ScimagoJR Scimago Lab , Copyright 2007-2024. Data Source: Scopus®

Cookie settings

Cookie Policy

Legal Notice

Privacy Policy

• August 24, 2024
• The ISPRS Foundation

  International Society for Photogrammetry and Remote Sensing  

» Instructions for ISPRS Archives Production

» Guidelines for Authors (Orange Book)

» Review Process for ISPRS Archives

» Search within The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences

» Title and Author Search (2011 and newer)

» ISPRS Ethics Code for Publications

The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences (ISPRS Archives) is the series of peer-reviewed proceedings published by the International Society of Photogrammetry and Remote Sensing (ISPRS). In the early years of the Society, Archive Volumes were published independent of Congress or Technical Commission Symposia. Archives resides at ITC in The Netherlands.-->

Since Volume XXXII-3/W14, 1999, the Archives are open access publications, they are published under the Creative Common Attribution 3.0 (4.0 since June 2017) License, see https://publications.copernicus.org/for_authors/licence_and_copyright.html for details.

The Archives are listed in the ISI Conference Proceedings Citation Index (CPCI) of the Web of Science, SCOPUS, and the Directory of Open Access Journals (DOAJ).

The publication costs for each Archives volume are settled through the corresponding conference. Therefore, authors do not have to pay article processing charges.

The Archives are listed in the ISI Conference Proceedings Citation Index (CPCI) of the Web of Science, SCOPUS, the E/I Compendex, and the Directory of Open Access Journals (DOAJ).

For decades the physical repository of the archive was hosted by ITC, University of Twente in the Netherlands. ISPRS gratefully acknowledges this support. In 2014 the repository was moved to the Technical Information Library (TIB) at Leibniz Universität Hannover, and is now gradually being made available to the public, as all volumes are being digitised and integrated into this web interface. TIB performs this task as a service to the Society and the spatial science community. ISPRS is greatly indebted to TIB for this kind offer.

ISPRS Archives and Annals - automatic citation counts in Google Scholar enhanced In order to solve existing problems with Google Scholar the domain part in the URLs for the two ISPRS proceedings series, the Archives and the Annals, have recently been changed. According to the publisher Copernicus, the old URLs will remain valid to avoid any broken links when referencing existing publications. Nevertheless, we would like to point out that using DOI for the reference is the best choice, as it ensures permanent validity.

The following table contains a list of all the ISPRS Archives.  

Since 2000, GITC is responsible for the Archives publications.

The copyright of the articles remain with the authors. For joint events with other organizations there may exist other regulations.

Archives eISSN Number: 2194-9034 (Internet and USB) Archives ISSN Number: 1682-1750 for hard copy (Print) Archives ISSN Number: 1682-1777 for soft copy (CD-ROM)

Non ISPRS Proceedings are listed seperately under "Proceedings and Presentation of Workshops, Symposia or Congresses related to ISPRS" here.

Other ISPRS related events with Online Proceedings

The ISPRS Foundation Brochure  

The International Society for Photogrammetry and Remote Sensing is a non-governmental organization devoted to the development of international cooperation for the advancement of photogrammetry and remote sensing and their applications. The Society operates without any discrimination on grounds of race, religion, nationality, or political philosophy.

Latest Posts

Incredible template, new features, new terms and conditions, useful links, useful external links, our contact.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Springer Nature - PMC COVID-19 Collection
• PMC10160711

The Emergence of Mpox: Epidemiology and Current Therapeutic Options

Samriddhi ranjan.

1 College of Public Health, George Mason University, 4400 University Drive Fairfax, Fairfax, VA 22030 USA

Kanupriya Vashishth

2 Advance Cardiac Centre Department of Cardiology, PGIMER, Chandigarh, 160012 India

3 NGO Praeventio, Tartu, Estonia

Hardeep Singh Tuli

4 Department of Biotechnology, Maharishi Markandeshwar Engineering College, Maharishi Markandeshwar (Deemed to Be University), Mullana-Ambala, Haryana, 133207 India

Associated Data

This document includes citations for all the data that were analysed throughout the literature review.

The world recently witnessed the emergence of new epidemic outbreaks like COVID-19 and mpox. The 2022 outbreak of mpox amid COVID-19 presents an intricate situation and requires strategies to combat the status quo. Some of the challenges to controlling an epidemic include present knowledge of the disease, available treatment options, appropriate health infrastructures facilities, current scientific methods, operations concepts, availability of technical staff, financial funds, and lastly international policies to control an epidemic state. These insufficiencies often hinder the control of disease spread and jeopardize the health of countless people. Also, disease outbreaks often put a huge burden on the developing economies. These countries are the worst affected and are immensely dependent on assistance provided from the larger economies to control such outbreaks. The first case of mpox was reported in the 1970s and several outbreaks were detected thereafter in the endemic areas eventually leading to the recent outbreak. Approximately, more than 80,000 individuals were infected, and 110 countries were affected by this outbreak. Yet, no definite vaccines and drugs are available to date. The lack of human clinical trials affected thousands of individuals in availing definite disease management. This paper focuses on the epidemiology of mpox, scientific concepts, and treatment options including future treatment modalities for mpox.

Introduction

Amidst the COVID-19 pandemic, another public health concern emerged as a potential threat to afflict people globally, i.e. an abrupt increase in the incidence of mpox (monkeypox) cases. Indeed, starting from mid-May 2022, cases of human mpox have significantly risen in several non-endemic countries worldwide, leading to the declaration of the ongoing outbreak of mpox as a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO) in July 2022 [ 1 , 2 ]. Mpox disease is caused by the mpox virus (MPXV), a double-stranded DNA virus from the Orthopoxvirus genus, belonging to the Poxviridae family [ 2 , 3 ]. The same genus includes the variola virus, a known causative agent of smallpox [ 2 ]. Genetically, MPXV is identified with two types of clads. Clad I, also known as Congo Basin clad, is mostly clustered in the Central-South Cameroon region till DRC. Infections from this clad are more severe with case fatality rates (CRF) > 10%. Clad II also referred to as West African clad, commonly distributed in western Cameroon to the Sierra Leon area, is further divided into sub-clad groups as IIa and IIb (also now referred to as clad III) having a CRF < 1% [ 4 , 5 ]. Overall reported human case fatality rates (CFRs) range between 3.6 and 10.6% in the endemic regions [ 2 ]. In the current 2022 outbreak, clad IIb was predominant [ 6 , 7 ]. To date, the exact animal reservoir for the mpox virus (MPXV) has remained unknown. However, few native African rodents (Gambian giant rats) and squirrels are suspected to be natural reservoirs of the virus. Common species which were frequently infected with MPXV are squirrels, Gambian giant rats, strip mice, dormice, and primates [ 8 ].

Emergence of Mpox

The first outbreak of mpox was reported in 1958 in a group of 10 captive monkeys at the Statens Seruminstitut, Copehengan, Denmark, and Centre d’Enseignement et de Recherches de Medecine aeronautique, Paris. No human infection was reported in individuals who were in close contact with infected monkeys. Subsequently, the mpox outbreak occurred for the first time in humans between 1970 to 1971 [ 9 ]. The first case was reported in a 9-month-old boy residing in a remote village of the Democratic Republic of Congo (DRC), admitted to a local hospital suspected of smallpox infection. Samples from infected individuals were sent to the WHO Smallpox Reference Center, Moscow, revealing mpox infections in virus isolates [ 10 ]. When inspected from family, monkeys were part of the diet, and their skins were also processed in this area. However, no other cases including secondary infections were reported in the community. Nonetheless, seven more cases were reported during this time period [ 9 ]. The World Health Organization in 1967 took the initiative to collaborate with laboratories to conduct cooperative studies. This was to conduct serological surveys, identify mpox outbreaks, and determine the natural foci of the virus. However, these surveys failed to state any major findings and concluded mpox is not a widespread disease and can exist only in the local environment [ 9 ]. Ever since, there has been a subsequent upsurge of mpox cases, mostly recorded in the DRC province. Approximately, 80% of the cases were reported in this region from the years 1970–1997 [ 11 ]. For the past five decades, DRC is the most affected country with mpox; no other country had reported an mpox outbreak to such an extent [ 12 ].

The initial mpox outbreak that was reported in DRC mostly affected children below 10 years of age. A slight male predominance was observed in the systemic review conducted by Beer and Rao [ 11 ]. Most of the initial outbreaks occurred among individuals living in small rural areas or residing close to humid evergreen tropical forests or individuals commonly involved with bushmeat hunting [ 11 ]. Geographically, the spread of infection from 1970 to 2003 concentrated in the Central and Western parts of Africa (Table 1). Countries which frequently reported infections were Cameroon, the Central African Republic, Gabon, Sierra Leone, Liberia, Nigeria, and Cote d’Ivoire, yet greater outbreaks were mostly detected in DRC [ 13 ]. An active surveillance programme was carried out by WHO between the years 1981 to 1986 reporting total confirmed cases of 338 and 33 deaths, an almost 20 times rise in the reported case after the surveillance [ 10 , 11 ]. A slight drop in the incidence of disease was observed between the period of 1993–1995. But soon after, DRC witnessed a major outbreak from 1996–1997 [ 13 ]. A total of 511 cases were recorded with a surge in secondary transmission rates of up to 78% and a fatality rate between 1 and 5% [ 10 , 13 ].

In 2003, the mpox outbreak occurred for the first time in the USA, outside the African continent. The index case was a 3-year-old girl, bitten by an infected prairie dog, imported from Ghana along with other African rodents to the USA [ 14 ]. A total of 71 cases were reported, including both suspected and laboratory-confirmed cases, as per the CDC report [ 15 ]. During the period of 2005, mpox was registered for the first time in the dry savannah region of Sudan. Overall, 40 cases both suspected and confirmed were recorded. In this outbreak, a change in the genomic structure of MPXV was observed as compared to the MPXV traditionally reported in DRC suggesting the adaptability of MPVX in dry regions from humid evergreen tropical forests [ 10 ]. In the year 2018, mpox travelled for the first time to the UK and was reported in the European continent. Only two cases were registered, in individuals, which had a travel history to Nigeria [ 16 ]. Nevertheless, with the advent of 2022, the world saw a major outbreak of mpox (Table ​ (Table1 1 ).

Decade-wise spread of mpox across different countries between 1970 and 2020 9,10

Mpox Outbreak 2022

Mpox is endemic in Central and West Africa, where hundreds of cases were detected annually for many years, acquired mostly from wild animals and most rarely from infected humans [ 1 , 3 ], which results in a sporadic spillover of cases in humans as observed in the MPVX endemic regions [ 5 ]. However, in the 2022 outbreak of mpox, most of the cases were reported in non-endemic countries like N. America, S. America, and Europe (Fig.  1 ) [ 17 ]. Although the origin of the 2022 outbreak is still unknown, it is highly likely that the initial infection has been imported from an endemic country, allowing the circulation of the virus through close physical contacts among humans [ 1 , 18 ]. For the first time, mpox was documented with transmission chains in countries which had no immediate contact with Central or Western Africa [ 19 , 20 ]. This suggests a probability of undetected MPXV circulating in the local population in the outbreak-hit regions causing disease transmission in humans [ 17 ]. Being a DNA virus, mpox is more stable in nature and may have possibly evolved as a potent virus causing infections in humans in the due course of time [ 17 ]. Daniel et al. reported 6–12 times higher mutation rates in mpox as previously estimated [ 6 ]. Human to human transmissibility of mpox has also evolved in these decades [ 21 , 22 ]. Vertical infection of mpox has been also reported. Pregnant mothers infected with mpox had miscarriages during the first trimester of pregnancy [ 6 ]. Perinatally acquired mpox infection was registered in a 9-day year old neonate as well [ 23 ]. Transmissibility of infection within the family especially from parents to children have also been stated to increase [ 20 , 22 ]. The degree of transmissibility of the diseases, popularly known as R 0 , reported in the 1980 for mpox was 0.83. However, in the 2022 outbreak, the R 0 reported was 1.1–2.4 [ 21 , 24 ]. Pan et al. suggested the increase in the R 0 is due to decreased immunity of individuals due to the absence of smallpox immunization and high contact rates of infection in the MSM community [ 6 ].

Countries reporting mpox historically vs countries reporting an mpox outbreak as recorded in an early March 2023 report by CDC 19

As per the WHO, till 17 March 2023, the total confirmed cases for mpox were 86,601, with 1265 probable cases reported with 112 deaths. Globally, 110 countries were affected by mpox so far (Fig.  2 ) [ 20 ]. Approximately 34.7% of cases were reported in America, the worst affected country [ 20 ]. Majority of the infection occurred through household contacts (43%) and by sexual encounters (43%) [ 20 , 22 ]. Commonly affected individuals were young males who were not vaccinated against smallpox and have had sex with men. There was a slight male predisposition, with the median age reported as 34 years (IQR: 29–41). Around, 98% of individuals who were infected were either gay or bisexual, among which 41% of the people were HIV infected [ 4 ].

Mpox number of cases and deaths recorded in early March 2023 across the continent as per the report by CDC 19

On 23 July 2022, mpox was declared a public health emergency by the Public Health Emergency of International Concern (PHEIC), depicting a risk of international spread, along with significant international coordination to control the disease [ 25 ].

Clinical presentation of this disease includes three distinct phases, i.e. incubation, prodrome, and rash [ 2 ]. The incubation period can last for 3 to 20 days with the median being 7 days followed by the prodrome phase that is characterized by lethargy, myalgia, headache, fever, and lymphadenopathy which may last up to 5 days (Fig.  3 ) [ 2 , 4 , 18 ]. Lymphadenopathy is one of the critical features of the progression of the disease and often reported before the development of skin lesions [ 18 ]. Fever is usually followed by multiple papular, ulcerative, and vesiculopustular skin lesions [ 4 ], which progress from macules to papules, vesicles, pustules, crusts, and lastly scab, presenting for up to 4 weeks [ 2 , 18 ]. In 95% of the cases, skin lesions appears [ 4 ]. Common anatomical sites for skin lesions were anogenital with approximately 73% of cases followed by trunk, arms or legs, face, and eventually palms and soles, only accounting for 10% of the cases. Lesions developed contain infectious virus particles, through which the infection can be transmitted directly with human contacts [ 2 ]. Secondary complications include pneumonia, encephalitis, keratitis, gastroenteritis, sepsis, and secondary bacterial infections, affecting mostly patients with a previous diagnosis of HIV infection [ 2 , 4 , 5 ].

Common features reported in mpox infection 4

Current Treatment Modalities and Prevention

The strategy for the prevention and treatment of mpox is very similar to the treatment of Orthomyxovirus infection [ 26 ]. The 2022 outbreak revealed the urgency to control the spread of mpox as it has caused a potential threat in many countries [ 27 ]. Presently, there is no definitive cure for mpox infection, mild symptoms are manageable, and further complications can be avoided in patients with mpox with the help of supportive care [ 28 , 29 ]. Studies have depicted that patients with mild symptoms recover without any treatment [ 30 – 32 ]. Treatment options available for smallpox are also effective in the treatment of mpox, as the clinical presentation of mpox and smallpox is very similar. These include the vaccinia vaccine, vaccinia immune globulin (IVG), and antiviral agents such as cidofovir, tecovirimat, and brincidofovir [ 32 ]. Furthermore, CDC recommends the use of the potential treatment options should be done depending upon the severity of the cases and for serious emergency cases, as the current drugs pose severe adverse effects, and their therapeutic efficacy is still uncertain [ 33 ]. Antiviral drugs are a choice of treatment in immunocompromised patients, in patients with complicated lesions, in pregnant women infected with mpox, in breast-feeding women, and in the paediatric population [ 34 ]. Tecovirimat is the first line of action antiviral recommended for the treatment of smallpox; it works by inhibiting the viral envelope protein, thereby blocking the final steps of virus maturation and release from infected cells, inhibiting the spread. As per the CDC guidelines, emergency access use of tecovirimat is allowed for compassionate use, for the treatment of Orthopoxvirus infections, such as mpox [ 35 , 36 ]. Cidofovir and its oral analogue brincidofovir are commonly approved drugs for the treatment of smallpox; both act by inhibiting viral DNA polymerase. Different studies have evaluated the effect of brincidofovir against Orthopoxvirus infections [ 37 ]. Studies done by Lanier et al. and others on the effect of cidofovir and brincidofovir have been evaluated for mpox with some success [ 34 , 37 ]. As per the recommended guidelines by CDC, preexposure smallpox vaccination has been advised for veterinarians, monkeypox contacts, healthcare workers caring for mpox patients, researchers, and field investigators [ 38 ]. Prior immunization with the smallpox vaccine has demonstrated some proven protective effects against mpox due to the cross-protective immunity provided by the smallpox vaccine. Furthermore, the severity of clinical manifestations is also reduced [ 39 ]. Currently, three available smallpox vaccines with the US national stockpile, i.e. JYNNEOSTM, ACAM2000, have been licenced (2007) for smallpox, the most recent being Aventis Pasteur Smallpox Vaccine (APSV) which could be potentially used for mpox on a case-to-case basis, under an investigational new drug (IND) protocol. JYNNEOSTM, a third-generation and live viral vaccine, is produced from the modified vaccinia Ankara-Bavarian Nordic [ 40 – 42 ]. Licenced in 2019, JYNNEOSTM is an attenuated non-replicating orthopoxvirus. It is now indicated for both smallpox and mpox prevention for adults. Further, ACAM2000, a second-generation vaccine constituted of live vaccinia virus, under the emergency access ACAM2000 is allowed for mpox during the outbreak. Researchers have demonstrated that these vaccines can be used as pre- and post-treatment options, i.e. either in preventing the infection and the disease or in ameliorating the infection and disease [ 34 , 43 , 44 ]. Studies have demonstrated that pregnant women, children less than 8 years of age, and immunocompromised patients should be given antiviral treatment than vaccination. These vaccines, although approved, have shown some local and systematic side effects such as fever, muscle pain, vaccinia, abdominal and back pain, fatigue, headache, lymphadenopathy, etc. [ 42 – 44 ]. Researchers have also highlighted the need for maintaining appropriate social barriers such as avoiding close contact with affected individuals, avoiding contact with skin lesions of individuals infected with MPXV, etc. [ 44 – 46 ]. Vaccinia immune globulin intravenous (VIGIV) is a choice of treatment in case of severe infection with mpox, though there is a paucity of data about its effectiveness in treating mpox. VIGIV is also under SNS and can be administered under investigational new drugs held by CDC [ 29 , 30 , 47 – 49 ]. Therefore, the treatment options and the repurposing of vaccines need to be considered on a case-to-case basis depending on the severity of cases and the immune state of patients [ 50 ] (Fig. ​ (Fig.4 4 ).

A Symptoms and B mechanism of action of mpox antiviral therapy: cidofovir, brincidofovir, vaccinia immune globulin, and tecovirimat [ 50 ] 

Key Fundamental Findings of the Narrative Review

Some major key findings related to mpox are as follows: mpox was solely endemic to the region of DRC [ 11 ]. There has been a slow and steady increase in mpox cases which has adapted itself to develop into the current outbreak. Secondly, the 1996–1997 DRC outbreak highlighted the increase in secondary transmission rates of mpox, potentially getting adapted to spread in the human population [ 13 ]. Thirdly, the MPXV had adapted to thrive itself from the humid evergreen regions to the dry savannah region of Sudan, as observed in the 2005 outbreak, thus further demonstrating its environmental adaptability to flourish [ 10 ]. Lastly, international travel and commerce have given a wider chance for the disease to spread as reported in the 2003 and 2018 outbreaks of mpox in the USA and the UK [ 14 , 16 ]. All these above factors have led to the 2022 outbreak of mpox, affecting every continent across the globe (Fig.  5 ).

Global spread of mpox in 2023 outbreak 19

Most of the consistent outbreak guidelines available from WHO or CDC only account for people with a high risk of exposure; these guidelines are based on the best available evidence which is based upon risk–benefit analysis and other factors [ 51 ]. Available drugs for the treatment of choice are also limited and lack evidence-based studies in humans [ 29 , 30 , 48 ]. This depicts an extensive need to increase the sustainable funding option to enhance our understanding of the development of new drugs and vaccines to curtail the spread of mpox.

Implication in Future Research

The environmental, behavioural, and social reasons behind the 2022 mpox outbreak remain unknown to date [ 1 ]. A deeper understanding of mpox genetics and biochemistry is essential to control its outbreak. It is currently unclear how mpox is closely related and linked to the viral strain that is primarily found in western Africa, as well as the potential routes of rapid transmission. To further understand the immune defence mechanisms against MPXV, more research is needed on the human systemic and mucosal immune responses. As DNA viruses are more adept to correct mutations; therefore, it is unlikely that the mpox virus will suddenly change during human transmission [ 24 , 52 ]. It is yet unknown, whether vaccinations and earlier infections have given the population immunity. Additionally, exploratory studies are required to pinpoint the precise mpox virus reservoir, understand how the virus spreads naturally, and determine the causes of the present increase in cases across several nations. Currently, no potent drugs are available and limited evidence-based studies are being conducted for the treatment of mpox [ 29 ]. Most of the available choices of treatment are discussed in this paper (Fig.  6 ). Therefore, it becomes essential to investigate the domain of natural products with antiviral properties. This provides alternative treatment options, to prevent human to human spread of infection and restrict virus amplification in the host organisms. There is a recent increased interest among the scientific community to look into the numerous bioactivities of structurally unrelated natural compounds [ 53 , 54 ]. Plant-derived polyphenol resveratrol has beeb shown to significantly suppress replication of MPXV affecting probably the viral DNA synthesis and inducing a comparable effect to the well-characterized Orthopoxvirus inhibitor, i.e. cytosine-1-β- d -arabinofuranoside (AraC) [ 55 ]. Due to the pleiotropic action of natural compounds and lack of systemic toxicity, plant-derived agents may represent target compounds to be explored in future clinical trials to enrich the drug arsenal against Orthopoxvirus infections. Parallel to this, early detection of infected patients who are potentially capable of transmitting the infection is also crucial, pointing to the need for improved diagnosis (particularly in atypical clinical presentations and asymptomatic cases), and better availability of molecular tests. Besides, such continual efforts of preclinical scientists and pharmaceutical companies, availability of health infrastructures, and medical staff are of critical importance—a situation still aggravated by the ongoing COVID-19 pandemic. A high-risk patient population is possibly in danger of mpox nosocomial transmission and deserves more attention. Therefore, it is crucial to administer the proper supportive care [ 24 ]. Consequently, it is necessary to improve genomic sequencing capabilities to identify the mpox viral clade(s). The primary necessities are to combat the spread of mpox while dealing with the ongoing COVID-19 pandemic and to include suitable and timely information campaigns for people at risk. It is challenging to create an evidence-based classification of drug safety and effectiveness having a brief history of mpox. Further studies on various animal models, which may affect medication exposure, are also encouraged. The focus of larger research should be on identifying the patients who are most at risk for consequences from mpox infection as well as the best timing for initiating and completing antiviral therapy.

Different treatment modalities in mpox

The emergence of new diseases is one of the incessant threats which mankind can face. Persistent interference between the environment and humans creates an opportunity for new infections to evolve. Over 75% of the pathogens, which are newly emerging, are zoonotic in nature [ 56 ]. Several diseases like HIV/AIDS, Nipah, SARS, and Ebola including mpox have recently appeared. International travel and commerce and human behaviour often help disease to spread [ 56 ]. With the first emergence of mpox in 1958, little is still known about its reservoir host and vector of the disease. Despite repeated outbreaks of mpox over the past years, it has failed to gather scientific attention. There is a lack of understanding of mpox transmission dynamics and disease evolution. In the areas endemic to mpox, regular disease surveillance is lacking. This also includes the need to promote funding for capacity building required for surveillance of the disease, research activities, and testing facilities [ 17 , 57 ]. The role of central bodies like the World Health Organization plays a major role in controlling such outbreaks. However, non-compliance to guidelines and regulations by health agencies like WHO severely impacts the control measures [ 25 ]. Boosting vaccine development and effective drug development is essential to prevent future outbreaks. In addition, new plant-derived products could be further developed and can be promoted as they potentially have lesser side effects for mpox treatment.

Abbreviations

Author Contribution

SR, KV, and KS: conceptualization and writing; HST: editing and proofreading. All authors reviewed the manuscript.

Data Availability

Compliance with ethical standards.

Not applicable.

All authors have their consent to publish.

The authors declare no competing interests.

This article does not contain any studies with human or animal subjects performed by any of the authors.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Samriddhi Ranjan, Email: ude.umg.evilnosam@najnars .

Kanupriya Vashishth, Email: [email protected] .

Katrin Sak, Email: [email protected] .

Hardeep Singh Tuli, Email: [email protected] .